Crossmark

A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors

Crossref DOI link: https://doi.org/10.1186/s12885-025-14982-4

Published Online: 2025-10-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Jian

Liu, Xiaojun

Du, Yiqun

Mu, Yuxin

Meng, Yanchun

Sun, Yan

Zhang, Ling

Chen, Chris

Cullberg, Marie

Fan, Ethan

Hu, Xichun
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2025-10-14

Version of Record valid from 2025-10-14
More Information

Article History

Received: 17 June 2025

Accepted: 3 September 2025

First Online: 14 October 2025

Declarations

:

: The study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council for Harmonisation/Good Clinical Practice, applicable regulatory requirements, and the sponsor policy on bioethics. The study was approved by the Medical Ethics Committee of Fudan University Shanghai Cancer Center on June 17, 2020 (approval no 2005217-11).All patients provided signed informed consent before admission to the study.

: Not applicable.

: LZ and EF are employees of AstraZeneca. MC and CC are former employees of AstraZeneca and may have ownership, options, and/or interests in AstraZeneca stock. XH, YD, XL, Y Mu, Y Meng, and YS declare no competing interests.

Document is current

Any future updates will be listed below